Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy

Journal of Investigative Dermatology

Volumn 111, Issue 6, 1998, Pages 1034-1039

  Okamoto, Tetsuro ^a   Irie, Reiko F ^a   Fujii, Shigeyuki ^a   Huang, Sharon K S ^a   Nizze, Anne J ^a   Morton, Donald L ^a   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Autoantibodies; Autoimmunity; Human clinical studies; Tumor immunity

Indexed keywords

AUTOANTIGEN; BCG VACCINE; IMMUNOGLOBULIN G; MELANOMA VACCINE; TUMOR CELL VACCINE; TYROSINASE RELATED PROTEIN 2; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DEPIGMENTATION; HUMAN; HUMAN CELL; HYPOPIGMENTATION; IMMUNE RESPONSE; IMMUNOGENICITY; INTRADERMAL DRUG ADMINISTRATION; MELANOMA; PRIORITY JOURNAL; SKIN TUMOR; VITILIGO;

EID: 0032457224     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.1998.00411.x     Document Type: Article

References (38)

1. Adema GJ, de Boer AJ, Vogel AM, Leonen WAM, Figdor CG: Molecular characterization of the melanocyte lineage-specific antigen gp100. J Biol Chem 269:20126-20133, 1994
2. Barth A, Morton DL: The role of adjuvant therapy in melanoma management. Cancer 75:726-734, 1996
3. Berd D, Mastrangelo MJ, Lattime E, Sato T, Maguire HC: Melanoma and vitiligo: immunology's Grecian urn. Cancer Immunol Immunother 42:263-267, 1996
4. Bloom MB, Perry-Larry D, Robbins PF, Li Y, El-Gamil M, Rosenberg SA, Yang JC: Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 185:453-459, 1997
5. Bouchard B, del Marmol B, Jackson IJ, Cherif D, Dubertret L: Molecular characterization of a human tyrosinase- related protein-2 cDNA patterns of expression in melanocytic cells. Eur J Biochem 219:127-134, 1994
6. Chen YT, Stockert E, Jungbluth A, Tsang S, Coplan KA, Scanlan MJ, Old LJ: Serological analysis of Melan-A (MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci USA 93:5915-5919, 1996
7. Doi F, Chi DDJ, Charuworn BB, Conrad AJ, Russell J, Morton DL, Hoon DSB: Detection of β-human chorionic gonadotropin mRNA as a marker for cutaneous malignant melanoma. Int J Cancer 65:454-459, 1996
8. Fishman P, Merimski O, Baharav E, Shoenfeld Y: Autoantibodies to tyrosinase, the bridge between melanoma and vitiligo. Cancer 79:1461-1464, 1997
9. Fleiss J: The analysis of data from matched samples. In: Statistical Methods for Rates and Proportions. New York, John Wiley, 1981, pp. 112-132
10. Griffith TS, Ferguson TA: The role of Fas-L induced apoptosis in immune privilege. Immunol Today 18:240-244, 1997
11. Harnig R, Cui J, Bystryn JC: Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 97:1078-1080, 1991
12. Hayashi Y, Hoon DSB, Foshag LJ, Park MS, Terasaki PI, Morton DL: A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine. Cancer 72:750-759, 1993
13. Hoon DSB, Irie RF: Current status of human melanoma vaccines. Biodrug 7:66-84, 1997
14. Hoon DSB, Wang Y, Sze L, et al: Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers. Cancer Res 53:5244-5250, 1993
15. Hoon DSB, Yuzuki D, Hayashida M, Morton DL: Melanoma patients immunized with melanoma cell vaccine induce antibody response to recombinant MAGE-1 antigen. J Immunol 154:730-737, 1995a
16. Hoon DSB, Wang Y, Dale PS, et al: Detection of occult melanoma cells in blood with a multiple-marker polymerase chain assay. J Clin Oncol 13:2109-2116, 1995b
17. Hoon DSB, Okamoto T, Wang H-J, et al: Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients? J Clin Oncol 16:1430-1437, 1998
18. Isenberg DA, Rahman MA, Ravirajan CT, Kalsi JK: Anti-DNA antibodies: from gene usage to crystal structures. Immunol Today 18:149-153, 1997
19. Jones PC, Sze LL, Liu PY, Morton DL, Irie RF: Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 66:249-254, 1981
20. Livingston PO, Wong GYC, Adluri S, et al: Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044, 1994
21. del Marmol V, Beermann F: Tyrosinase related proteins in mammalian pigmentation. FEBS Lett 381:165-168, 1996
22. Mattes MJ, Thomson TM, Old LJ, Lloyd KO: A pigmentation-associated, differentiation antigen of human melanoma defined by a precipitation antibody in human serum. Int J Cancer 32:717-721, 1983
23. Merimsky O, Baharav E, Shoenfeld Y, Chaitchik S, Tsigelman R, Cohen-Aloro D, Fishman P: Anti-tyrosinase antibodies in malignant melanoma. Cancer Immunol Immunother 42:297-302, 1996
24. Morton DL, Foshag LJ, Hoon DSB, et al: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216:463-182, 1992
25. Naftzger C, Takechi Y, Kohda H, Hara I, Vijayasaradhi S, Houghton AN: Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci USA 93:14809-14814, 1996
26. Naughton GK, Eisinger M, Bystryn JC: Antibodies to normal human melanocytes in vitiligo. J Exp Med 158:246-251, 1983
27. Morris DA, Kissinger RM, Naughton GM, Bystryn JC: Evidence for Immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 90:783-789, 1988
28. Okamoto T, Kaneda Y, Yuzuki D, Huang SKS, Chi DDJ, Hoon DSB: Induction of antibody response to human tumor antigens by gene therapy using a fusigenic viral liposome vaccine. Gene Ther 4:969-976, 1997
29. Orlow SJ, Boissy RE, Moran DJ, Pifko-Hirst S: Subcellular distribution of tyrosinase and tyrosinase-related protein-1: implications for melanosomal biogenesis. J Invest Dermatol 100:55-64, 1993
30. Richards JM, Mehta N, Ramming K, Skosey P: Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10:1338-1343, 1992
31. Rosenberg SA: Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunology Today 18:175-182, 1997
32. Sarantou T, Chi DDJ, Garrison DA, Conrad AJ, Schmid P, Morton DL, Hoon DSB: Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res 57:1371-1376, 1997
33. Song YH, Connor E, Li Y, Zorovich B, Balducci P, Maclaren N: The role of tyrosinase in autoimmune vitiligo. Lancet 344:1049-1052, 1994
34. Spagnoli GC, Schaefer C, Willimann TE, et al: Peptide-specific CTL in tumor-infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients. Int J Cancer 64:309-315, 1995
35. Takechi Y, Hara I, Naftzger C, Xu Y, Houghton AN: A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin Cancer Res 2:1837-1842, 1996
36. Thomson TM, Mattes MJ, Roux L, Old LJ, Lloyd KO: Pigmentation-associated glycoprotein of human melanomas and melanocytes: a definition with a monoclonal antibody. J Invest Dermatol 85:169-174, 1985
37. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA: Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 184:2207-2216, 1996
38. Zhai Y, Yang JC, Kawakami Y, et al: Antigen-specific tumor vaccines. Development and characterization of recombinant adenovinis encoding MART-1 or gp100 for gene therapy. J Immunol 156:700-710, 1996